Treatment with high-dose chloroquine (CQ) should not be recommended in patients with severe COVID-19 infection, according to findings of an interim analysis of data from a randomised trial published in *JAMA Network Open*.^[@CR1]^

In a double-blind phase IIb trial initiated in March 2020 which planned to enrol 440 adults hospitalised with severe COVID-19 in Brazil, patients were randomised to receive CQ 600mg twice daily for 10 days (high-dosage) or CQ 450mg twice daily on day 1 and then once daily for 4 days (low-dosage). The primary endpoint was reduction in the death rate by 50% or more with high-dosage versus low-dosage treatment. This unplanned interim analysis of 13-day data in 81 patients was recommended by an independent data safety and monitoring board due to safety concerns.

All patients also received azithromycin, and 92.5% and 86.8% of patients receiving high-dosage and low-dosage CQ, respectively, received oseltamivir.

Increased creatine phosphokinase levels were reported in 50.0% and 31.6% of patients receiving high-dosage and low-dosage CQ, respectively, and one patient developed severe rhabdomyolysis.

The proportion of patients who developed rate-corrected QT interval greater than 500ms was higher with high-dosage CQ (18.9% vs 11.1%), and the death rate at 13 days was significantly higher with the high-dosage regimen than with the low-dosage regimen (39 vs 15%; odds ratio 3.6; 95% CI 1.2, 10.6).

\"In this study, a high-dosage of CQ . . . given for 10 days concurrently with azithromycin and oseltamivir was not sufficiently safe to warrant continuation of that study group. Age was an important confounder and might be associated with the unfavorable outcomes. We recommend that similar dosages no longer be used for the treatment of severe COVID-19,\" said the authors.

\"Despite these discouraging findings, several other observations prevent concluding categorically that high-dose chloroquine was toxic and that the likely mechanism was arrhythmogenesis,\" commented Dr Stephen Fihn from the University of Washington, Seattle, USA and colleagues, in an accompanying editorial published in *JAMA Network Open*.^[@CR2]^ \"For the time being, prudent clinicians should discuss with patients and their families, when feasible, the potential risks of this drug and the uncertain benefits before initiating it,\" they said.
